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Abstract
The physiological process of aging is undeniable complex. Changes in metabolism (i.e.,
increased fat and decreased water content, decreased liver function secondary to loss of
hepatocytes leading to decreased metabolism, etc.) lead to an alteration in the pharmacokinetics
and pharmacodynamics of medications in the body. A drug may accumulate in the serum of the
body for a prolonged time secondary to diminished distribution. Disruption in the mechanism of
drug metabolism may result in the elder individual experiencing adverse effects from the
medication. The addition of morbidities into the mix enhances complexity whereby creating new
challenges as the result is generally polypharmacy. Individuals with multiple chronic conditions
are more likely to be on more medications. The more medications an individual is on increases
their risk for drug to drug interactions and subsequent adverse effects. Providing care for an older
individual (i.e., 60 or older), or an individual whose chronic conditions include dementia,
requires additional care. This works will analyze a patient case involving multi-morbidities,
dementia and polypharmacy. Through this patient situation, the need for interventions, such as
de-prescribing will be clearly demonstrated.
Keywords: deprescribing, inappropriate prescribing, polypharmacy, dementia, elderly
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De-prescribing, a Solution to the Issue of Polypharmacy:
Case Report and Review
Advancements in technology and ongoing discovery of new research findings in
medicine have led to individuals having a longer life expectancy. According to the National
Institute on Aging (2015), over half of the causation for the increase in life expectancy for
females of developed countries between 1850 and 1900 can be attributed to these individuals
living past 15 years of age. Prior to vaccinations, the culprits known for shortening the life
expectancy included infectious and parasitic diseases. However, vaccinations are now widely
available to counteract what used to be the "childhood killers." Individuals are living longer and
with that comes new challenges. Development and progression of chronic disease, in addition to
non-communicable diseases are among those challenges. Small strides have been made in the
medical management of chronic conditions, however the percentage of the population affected is
growing. Chronic disease was at one time, thought to be a death sentence. Learning how to
effectively manage all the associated factors of chronic disease is challenging. The extent of this
challenge is enhanced with the presence of co-morbid conditions. We continue to research these
diseases and improve prevention and management methods.
Chronic disease is further challenged by the normal physiological process of aging. The
complications of aging with chronic disease requires polypharmacy, which brings with it
additional risks. It is important to routinely review a patient’s medications to evaluate for
necessity. According to the National Institute of Health (NIH, 2016), roughly fifteen percent of
the population is 65 years or older. This age group contributes to thirty percent of outpatient
prescription costs. Evidence shows that over half of community dwelling elderly individuals
(ages 65 and older) in the USA and Australia have five or more daily medications. It
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demonstrates a directly proportional relationship between aging and the number of routine
medications.
Potentially inappropriate medications (PIMs) can be described as the medications
suggested to avoid prescribing to the elderly based on a clinical tool such as the AGS Beers
Criteria, STOPP/START, or Medication Appropriateness Index (Cooper et al., 2015). Various
studies have demonstrated the association between PIMs and adverse drug outcomes,
hospitalizations, diminished quality or life as well as mortality. Utilizing interventions to prevent
PIM and associated outcomes is longstanding. However, de-prescribing is a relatively new
concept, which can be explained as cutting down or discontinuing medications with the intended
outcomes of appropriate prescribing and elimination of the increased potential for adverse effects
(Page, Clifford, Potter, Schwartz, & Etherton-Beer, 2016). The challenges of PMIs that
necessitate an intervention such as de-prescribing, are clearly demonstrated in an unexpected
case study involving an elderly patient with polypharmacy. The issue of polypharmacy is one
that affects all age groups, in a variety of environments. The elderly population is vulnerable and
as such, are at a higher risk for the detrimental effects of polypharmacy.
Case Report
A 59-year-old Caucasian, overweight woman with multiple active health problems
presented to the clinic for follow-up on a recent hospitalization for UTI and fatigue. She had
been discharged from the hospital four days earlier on nitrofurantoin, and had three days left.
UTI symptoms were reportedly resolved. Endorsed ongoing fatigue for two months and noted a
new complaint of intermittent dizziness, often positional. Otherwise, reported she felt well. Past
medical history is significant for anemia, dementia, diabetes, COPD, hypertension, depression
and neuropathy. At that time, she was taking 12 different scheduled medications including, daily
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doses of losartan 50mg, furosemide 20mg and paroxetine 20mg, as well as twice daily doses of
metoprolol 50mg and quetiapine 200mg. Also, 300mg of gabapentin was scheduled three times
daily. As a resident at an assisted living apartment, she has staff to administer her medications.
The patient presented hypotensive with bradycardia, blood pressure 88/40 and heart rate
50. The remainder of her physical examination was fairly unremarkable. No apparent goiter,
edema, abdominal tenderness or mass. Laboratory results included: thyroid stimulating hormone
3.41 mI/UL, hemoglobin 12 g/dL, hematocrit 37%, platelets 400,000/mL, glucose 96 mg/dL,
blood urea nitrogen 9 mg/dL, creatinine 0.8 mg/dL, sodium 140 mmol/L, potassium 3.9 mmol/L,
aspartate aminotransferase 25 IU/L, alanine aminotransferase 11 IU/L, and albumin 4.1 gm/dL.
ECG interpretation revealed sinus bradycardia, HR 48 bpm. Assessment dictated the following
differential diagnoses: hypotension, hypothyroidism and anemia. Treatment for her hypotension
included the following interventions: push fluids, decrease metoprolol to 25mg two times per
day, discontinue furosemide, reduce dose of quetiapine to 150mg two times per day and return
for follow up appointment in one week.
Discussion
The case study discussed demonstrates the strong impact of polypharmacy in the aging
population. It denotes the importance of having the best interventions available. This leads to
many questions: how does de-prescribing polypharmacy compared with other available
interventions affect patient outcomes? How is this different in older patients? Or patients with
dementia?
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Evidence Search
The intention of this work is to further explore the practice of de-prescribing, specifically
in the older adult population. In the midst of this search, the author aimed to learn how deprescribing could be a solution to polypharmacy in aging individuals struggling with chronic
multiple morbidities or comorbid conditions. A thorough review of the literature was
accomplished by means of CINAHL, Cochrane, PubMed, and ScienceDirect electronic
databases. McKeever, Nguyen, Peterson, Gomez-Perez, and Braunschweig (2016) recommended
that a search of Mesh terms be conducted and, afterwards the Mesh terms should be listed with
not "Medline [sb]". Separating the searches of Medline and not-Medline allow for the
approximately 10% lost the by Medline search to be discovered through the second, not-Medline
search. This method allows the researcher to conduct a gold-standard search that is both,
proficient and clearly exhaustive to the reader.
Through the use the PubMed database, the achievement of an exhaustive search is quite
evident. The initial results were in the thousands. Limits were strategically placed to reduce the
number of results. English was selected as a limit, with the focus on the human species and the
full free text filter on to allow analysis of the documents entirety if selected. The 5-year limit was
placed to ensure current research findings in the database. The Mesh terms, "Deprescriptions" or
"Inappropriate Prescribing/prevention and control" or "Drug-Related Side Effects and Adverse
Reactions/prevention and control" and "Humans" were searched in the sequence displayed. The
related articles function was applied to limit the search. As previously noted, the not-Medline
search was conducted with the same 4 phrase sequence, however with not "Medline [sb]" after
"Humans". The not-Medline search yielded 31 findings, of which 10 met the criteria.
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Mateo and Foreman (2014) stressed that a researcher should use multiple databases
throughout their research to ensure that important findings are not missed. Keywords
"deprescription" and "elderly" were terms searched utilizing the ScienceDirect database. Limits
were not necessary. The search yielded 14 results, with only 2 being applicable to this works.
The CINAHL database was employed through the Boolean/Phrase search mode. The following
terms were utilized: “deprescribing” or “inappropriate prescribing” and “elderly”. In an effort to
decrease the number of findings the limits placed include: publication date between 2014 and
2017 for current results, and the English language. Results produced in the search were over 100.
Terms searched for on the Cochrane database include: “deprescribe” or “polypharmacy” or
“inappropriate prescribing or medical overuse”. A total of 21 results were yielded in this search.
The results of the PubMed, CINAHL, ScienceDirect and Cochrane databases were sifted
through to determine the relevant findings. This proved to be a challenging task as the majority
of the research findings in the listed databases were considered irrelevant to the author. In light
of this, additional studies were discovered through utilizing the “snowball” approach. Analysis
was completed on 11 of the articles discovered during these searches.
Grading the Evidence
Classification of evidence via a level grading system allows for the promotion of
confidence in the researcher’s findings. The evidence found throughout this research was graded
based on the AACN’s New Evidence-Leveling System. This system ranges from levels A-E and
M with the highest level starting at level A and the lowest level M.
Level A is classified as meta-analysis of controlled studies or meta-synthesis of
qualitative studies (Armola et. al, 2009). Randomized and non-randomized controlled studies are
level B evidence. Descriptive, correlational and quantitative studies as well as randomized
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controlled and systematic or integrative reviews with findings that are inconsistent would be
classified as level C evidence. Level D evidence includes clinical guidelines by professional
organizations that have been peer-reviewed. Case studies or expert opinions based on theory are
classified as level E evidence. The recommendations provided by a manufacturer is graded as
level M (Armola et. al, 2009).
The mission of the American Association of Critical Care Nurses (AACN) focuses on the
development of interventions that will lead to a better understanding of the resources in question
to allow members of the nursing profession to determine the best possible evidence for clinical
practice (Armola et. al, 2009). As a member of the nursing professional and a goal to yield strong
evidence for clinical practice, the AACN’s hierarchy of evidence is indubitably appropriate. The
levels of evidence for the 11 studies analyzed are as follows: 2 randomized control studies
(RCTs) fit the criteria for level B, and the remaining 9 fit the criteria for level C. All of the 7
level C studies are systematic review and/or meta-analysis that revealed inconsistent,
heterogeneous findings.
Synthesis of Findings
Cooper et al. (2015) demonstrated how validated screening tools (i.e., Medication
Appropriateness Index(MAI), Beers’ Criteria, Mcleod criteria, STOPP/START criteria,
Assessment of Underutilization of Medication and ACOVE) effectively reduce potentially
inappropriate prescribing (PIMs) in individuals ages 65 and older. It was noted that some of the
studies in the review did not consider the reverse effect of under-prescribing, which is another
major issue (especially in the older population). Utilization of MAI revealed a statistically
significant decrease in PIM. In addition, the other tools previously mentioned divulged a
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reduction as well though not significant. Unfortunately, the results of this review were
inconsistent which decreases its validity.
Another systemic review demonstrated similar findings regarding reductions in MAI in a
study population ages 65 and older, however there was additional focus on the presence of
dementia (Walsh, O’Riordan, Kearney, Timmons, & Byrne, 2016). The importance of reducing
PIM in individuals with dementia is amplified. This disease enhances the likelihood of the
individual experiencing an adverse effect as a result of polypharmacy, specifically
anticholinergics, antipsychotics, and benzodiazepines (Walsh, O’Riordan, Kearney, Timmons, &
Byrne, 2016). Our case patient came into the clinic on a high dose of quetiapine which is often
used in addition to an anti-depressant. This is likely why the patient in the case study has both
paroxetine and quetiapine on her active medication list. It is known that many of the mental
health medications carry a black box warning. Quetiapine is an anti-psychotic that holds a
blackbox warning. Its use in patients who are elderly with psychosis secondary to dementia
heightens their mortality risk. Antipsychotics increase the risk that the patient with dementia will
experience a cerebrovascular accident (American Geriatrics Society, 2015).
According to the Beers criteria (2015), paroxetine and quetiapine should be avoided in
ages 65 and older. The criteria states that quetiapine should not be administered to individuals
with dementia. Our case patient is younger than 65, however with her diagnosis of dementia and
multi-morbidities quetiapine is inappropriate. Her current medication list includes three CNSactive medications. This medication regimen places her at risk for adverse CNS effects, and
likely are at least partially to blame for her complaints of dizziness and persistent fatigue. The
furosemide and metoprolol are likely contributors to this as well.
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Interventions to improve patient adherence to medication regimens revealed
statistically significant increases in secondary outcomes including knowledge, physical
functioning, overall quality of life and general mood, cardiac and respiratory symptoms (Conn,
Ruppar, Enriquez, & Cooper, 2016). This demonstrates the importance of patient-centered
interventions to achieve patient-centered outcomes. Fried et al. (2014) found evidence indicating
de-prescribing can reverse symptoms. The evidence also showed that in addition to improvement
of physical functioning, de-prescribing enhances cognitive function. Interestingly, Scott,
Anderson, Freeman, and Stowasser (2014) demonstrated common themes related to barriers as
well as facilitators influencing the ruction of PIM. The themes discovered include awareness,
inertia (i.e. fear of the unknown), and self-efficacy (i.e., knowledge). Perhaps the educational
interventions for improving patient adherence to medication regimens mentioned earlier in this
paragraph would be effective interventions to the themes. Patients are much more likely to agree
with a plan for de-prescribing if they are cued in as to why. Reeve et al. (2013) identified barriers
and facilitators influencing patient agreement to de-prescribing. Understanding the
“appropriateness” of de-prescribing is one of the themes, which again indicates the need for
education.
According to Page, Clifford, Potter, Schwartz, and Etherton-Beer (2016), de-prescribing
exhibited a statistically significant decrease in mortality in two non-randomized control trials. A
systematic review including 19 studies implemented by Johansson et al. (2016) demonstrated a
downward trend in mortality associated with ongoing follow-ups post-hospitalization. Physicianled medication review verified statistically significant outcomes through reduction of PIM use in
the elderly (Tjia, Velten, Parsons, Valluri, & Briesache, 2013). Johansson et al. (2016) found
minimal evidence supporting reductions in hospital admissions secondary to reductions in PIM
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through a multi-disciplinary approach to medication review. One study showed a nonstatistically significant decrease in hospital admission. Whereas, Dreischulte et al. (2016)
demonstrated statistically significant reductions in hospital admissions for gastrointestinal bleeds
and heart failure. The results were non-statistically significant for acute kidney injury. Perhaps
the difference is related to the kidneys role in metabolism. Clyne (2015) verified the efficiency of
the pharmacist-led medication review in reducing PIM. This involved the utilization of OPTISCRIPT, which led to statistically significant reductions in proton pump inhibitors. Results for
all studies discussed are in Table 1.
De-prescribing involves a great deal more than the term implies. Multiple factors must be
taken into consideration including, a collaborative agreement between the patient and their
provider. Evidence supports the recommendation of de-prescribing, however this is often not
performed by providers secondary to challenges including time constraints and lack of patient
centered guidelines. More than a quarter of medications de-prescribed are re-initiated in less than
a year’s time. Re-initiation of previously de-prescribed medications has resulted in adverse
patient outcomes (Scott, Anderson, Freeman, & Stowasser, 2014). It is clear that de-prescribing
has shown beneficial outcomes. However, in order for this to be a successful intervention there
must be a patient-provider relationship built on trust.
When a provider is faced with the decision of whether or not to discontinue a medication,
the most important aspect that must be considered is the risks verses the benefits. This should
include the preferences of the patient and their family in addition to the availability of nonpharmacological treatment alternatives. The second step involves collaboration with the patient
and their family regarding the discontinuation process. Planning the strategy is the final step,

DE-PRESCRIBING, A SOLUTION

12

which should include a discussion with the patient regarding if and when the medication should
be re-initiated (Ferral, 2017).
The issue of polypharmacy is one that affects all age groups, in a variety of
environments. The elderly population is vulnerable and as such, are at a higher risk for the
detrimental effects of polypharmacy. Of the promising interventions known to combat this
problem, deprescribing is a more recent development with the potential to minimize the effects
of multiple medications use. Polypharmacy in older adults has been shown to yield many
negative results. This age group often carries with it a collection of multiple health problems,
leading to multiple medications and ultimately, polypharmacy. As a complication, the utilization
of multiple medications in the same elderly individual may end up in harm through adverse
effects, altered cognition, falls, as well as hospitalization or death.
De-prescribing is not merely a method of reducing medications; it should be utilized in an
effort to eliminate inappropriate medications. Polypharmacy in older adults has been shown to
yield many negative results. This age group often carries with it a collection of multiple health
problems, leading to multiple medications and ultimately, polypharmacy. As a complication, the
utilization of multiple medications in the same elderly individual may end up in harm through
adverse effects, altered cognition, falls, as well as hospitalization or death. Farrell et al. (2016)
developed guidelines for the de-prescribing process for patients 18 and older. The intention was
to construct a set of guidelines specific to the elderly population, however a decision was made
to broaden the age span based on the literature revealing insufficient evidence for this age group.
There is a plethora of research indicating the severity of the issue regarding
polypharmacy in the elderly population, however there is a lack of consistent evidence
supporting de-prescribing and other interventions to reduce polypharmacy. Concrete evidence is
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necessary for change. As outlined in this works, the age group with the greatest propensity of
harm as a result of polypharmacy is the elderly. For this reason, as well as the obvious
differences that are a consequence of aging (physiological vs. pathological), there should be a
separate set of guidelines for individuals ages 65 and older. This necessitates the attention of the
members in the health care community. It has been made abundantly clear that the elderly
population, ages 65 and older, is vulnerable. Additional research needs to be conducted to
determine how to further define the criteria for specific guidelines for this population.
Learning Points
1) When making a decision about whether or not to discontinue a medication, the emphasis
should be placed on the benefits versus risks.
2) The art of de-prescribing should be a patient-centered approach. This means considering
the preferences of the patient and their family and collaborating throughout the entire
process.
3) It is clear that de-prescribing has shown beneficial outcomes. However, in order for this
to be a successful intervention there must be a patient- provider relationship built on trust.
4) Deprescribing should place a greater emphasis on the technique of prescribing rather than
simply focusing on a decrease in medications prescribed.
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Authors/
Purpose and
Sample
Publication Design
Year

Cooper,
Cadogan,
Patterson,
Kerse,
Bradley,
Ryan,
Hughes/
2015

Update the
current
literature on the
effectiveness of
interventions in
reducing PIMs

Cochrane
systematic
review and
meta-analysis
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Data Collection, Measurement
Findings

N= 12

11 studies on pharmaceutical
care based intervention using a
Participants validated assessment tool
22,438
4 studies on patient education
and tools to schedule
medications to improve
compliance
5 studies on education to health
care providers and team
members
A single unifacitated study on
computerized decision support
7 validated screening tools were
utilized in the 12 studies (i.e,
Medication Appropriateness
Index, Beers' Criteria, Mcleod
criteria, STOPP/START criteria,
Assessment of Underutilization
of Medication and ACOVE)
Some studies focused on the
reduction of polypharmacy
without considering the

Strengths and
Limitations

AACN’s
New
EvidenceLeveling
System

Evaluation of quality of evidence
utilizing a GRADE approach

C

Randomization utilized in all
studies
No language restrictions
Studies with small sample size
and low quality based on GRADE
approach, resultant increased risk
of bias
Lack of allocation concealment
and protection against
contamination
Studies lacking a validated
assessment of under-prescribing
Effect estimate inaccuracy
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occurrence of the opposite effect
(i.e., under-prescribing)
Significant reduction in
inappropriate prescribing using
MAI
Reduction using the other tools
compared to no using a tool
Interventions not effective
against ADEs and
hospitalizations

Conn,
Ruppar,
Enriquez,
Cooper/
2016

Analyze
effectiveness of
interventions
implemented
for medication
adherence
through patient
outcomes
Synthesis
review and
meta-analysis

n= 141

Data collection via coding frame

23,318
Statistically significant results
participants were revealed in knowledge of
medication, function, specified
symptoms (i.e., depression, pain,
energy, cardiac and respiratory
and overall quality of life.
The most significant increase
was found in knowledge
Patient centered outcomes were
moderately increased postinterventions

Most studies utilized random
assignment
Use of allocation concealment
Presence of heterogeneous results
Significant risk of bias analysis

C
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Tjia, Velten,
Parsons,
Valluri,
Briesache/
2013

Analyze current
interventions
used to reduce
inappropriate
medication use
in the elderly

n= 36
13,906
subjects

Studies: 15 RCT, 4 non-RCT, 6
pre-post studies, and 11
case series.

Multiple studies with moderate to
high risk of bias secondary to
failing to adjust for potential
confounding variables as well as
non-blinded assessment of
outcomes

C

Pharmacy-led medication
review: 6 of 12 demonstrated
statistical analysis with 4 of the 6
noting results that were
Heterogeneity of results, unable
statistically significant. The
to complete meta-analysis
other 6 indicated variable results.

Systematic
review

Multi-disciplinary approach: 10
of 13 revealed statistical analysis
with 8 indicating statistically
significant results.
Statistically significant
medication reductions occurred
in 4 of 4 studies on academic
detailing, 5 of 5 studies of
medication reviews by
physicians and in audit/feedback

Walsh,
O’riordan,
Kearney,
Timmons,
Byrne, 2016

Update the
current
literature on the
effectiveness of
interventions in
reducing PIMs

n= 1,164
4 trials:
2 nonRTCs and
2 RTCs

Direct relationship noted
between presence of cohort
group and strength of study
comprehensive review utilizing
12 electronic databases
reductions in MAI were
statistically significant in 3
RTCs utilizing tools

All studies were at moderate risk
for bias

A
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Cochrane
systematic
review and
meta-analysis

Page,
Clifford,
Potter,
Schwartz,
EthertonBeer/ 2016

Discover the
level of safety,
effectiveness as
well as
practicability of
de-prescribing

N= 116
studies for
analysis

Evidence shows that deprescribing is practical, may not
influence mortality

Statistically significant reduction
in mortality with de-prescribing
revealed in non-RTCs, not
significant in RTCs

Fried,
O’Leary,
Towle,
Goldstein,
Trentalange,
Martin/
2014

Discover the
clinical
outcomes that
result from the
polypharmacy
management of
chronic
conditions in
community

N= 58

C

Broad inclusion criteria
Evidence is available to guide a
provider when the situation fits a
classic presentation meaning
there is a lack of applicability in
the guidelines

Systematic
review and
meta-analysis

Potential for language bias, limit
placed for English

Data elements included: design,
population, measure of
polypharmacy and main
findings.
All observational studies, most
cross sectional or longitudinal
cohort studies, few were case
control

Potential for bias based on
methodology
Small size of RCT and low
quality
Non-randomized studies

Adjustments were made for
confounding variables (i.e.,
chronic conditions)
Large and population based
cohort studies
Studies analyzed are
observational studies,
confounding is a greater issue

C
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members ages
65 and older
Systematic
review of
MEDLINE

23 studies analyzed falls as the
health outcome of
polypharmacy.
- 14 of 23 studies were rated
good.
- 12 of 14 found positive
association between
polypharmacy and the outcome.
Greater polypharmacy showed
association to outcomes, whereas
1-3 medications did not show
association.
14 studies analyzed ADEs as the
health outcome of
polypharmacy.
- 8 of 14 studies were rated
good. - 5 of 8 found association.
- 1 of the 5 showed association
only at use of 14 medications.
- 6 of 14 studies were rated fair
or poor and 4 of the 6 found an
association
10 studies analyzed
hospitalization or mortality as
the health outcome of
polypharmacy.
- 4 of the 10 were rated good and
found associations with the
outcome.
- 6 of 10 were rated fair or poor
and 3 of 6 found association
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15 studies analyzed multiple
health outcomes of
polypharmacy including
symptoms, function and
cognition.
- 11 of 15 studies were rated
good and all 11 found
association with one or more
outcomes.

Dreischulte,
Donnan,
Grant,
Hapca,
McCowan,
Guthrie,
2016

Determine how N= 34
the
practices
implementation
of “Data-Driven 33,334
Quality
Improvement in
Primary Care
(DQIP)” affects
the
hospitalization
course of
specified
conditions
RCT

A single study analyzed the
potential development of
Parkinson’s disease as the health
outcome of polypharmacy
Outcome measured was patient
exposure to 1 of 9 anticoagulating drugs defined as
high risk
Intervention implementation
revealed statistically significant
results found include decreased
admission to the hospital for
gastrointestinal bleed and heart
failure
Results were not significant
regarding hospital admission for
acute kidey injury

RCT design
B
Evaluation completed in primary
care
Continued positive outcomes
through analysis post-financial
incentive
Stepped-wedge design
Small study size
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Johansson,
Abuzahra,
Keller,
Mann,
Faller,
Sommeraue
r, Höck,
Löffler,
Köchling,
Schuler,
Flamm,
Sönnichsen
2016

Analyze
available
interventions
for
polypharmacy
to determine
their level of
efficiency

Clyne,
Smith,
Hughes,
Boland,
Bradley,
Cooper,
Fahey/ 2015

Analyze the
efficiency of
OPTI-SCRIPT
(multiintervention)
against PIMs

N= 25
21 RCTs
and 4 nonRCTS

systematic
review and
meta-analysis

RCT

n= 21
practices,
190
patients

Study focus: ages 65 and older
with polypharmacy (4 or more
medications)

Approach to assess quality
involved utilization of the Grade
Pro Tool

Interventions included electronic
based and non-electronic based
(i.e., Beers’ criteria)
- pharmacist, physician or
multiple discipline-led
medication review- inconsistent
results

Included studies were
heterogeneous

Interventions analyzed:
Hospitalization- 11 studies, 2
showed significant results, others
were inconsistent
Mortality- 19 studies, revealed a
downward trend with longer
follow up period inconsistent
results
Statistically significant results
Relevance to clinical practice
found in the reduction of
inappropriate prescribing of
Retention of study participants
proton pump inhibitors utilizing
the OPTI-SCRIPT intervention.
Potential selection bias reduced
via data collection by independent
OPTI-SCRIPT incorporates the
third party prior to minimization.
review of medications, pharmacy
visit to discuss potentially
Blindness to allocation
inappropriate medications and
the pharmaceutical based
Setting in primary care with
treatments guides on the web
available resources
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Scott,
Anderson,
Freeman,
Stowasser
/2014

To determine
what the
barriers and
facilitators to
reducing the
prescription of
inappropriate
medications
Systematic
review

N= 21

Analysis of study design and
aims, location and setting,
participants and enrollment
process, viewpoints of
provider/prescriber, PIMs
Methods included descriptive
survey, SSIs, interviews, group
discussions, focus groups
Utilization of focus groups and
partly structured interviews
Development of descriptive and
analytical themes utilizing
subthemes discovered
Collection through thematic
synthesis yielded 42 subthemes,
12 descriptive themes and 4
analytical themes

Possible limitation in external
validity
Assessment of quality utilizing
COREQ
-Ave score 17 (range 8—22)
-Better assessment of credibility,
dependability and transferability
of findings
Consistency with raw data
Interpretations were peer
reviewed, (aside for 1)
Obedience with reporting
requirements of ENTREQ
COREQ: researcher bias could
not be excluded
Ethics approval indeterminable in
5 studies
Terminology inconsistency and
poor indexing of search terms
interference with study findings

Intrinsic themes:
1) Awareness (i.e., poor insight,
discrepant beliefs and practice),
2) Inertia (i.e., fear of
Only 4 studies on polypharmacy,
unknown/negative outcome,
other studies on similar single
medication effect greater benefit medication/drug classes
than risk, prescribing is desired
by patient, challenge of cessation
and low priority)
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3) Self-efficacy (i.e., skills,
knowledge)
Extrinsic theme:
1) Feasibility (i.e., patient
resistance to change, limited
alternatives, time/effort needed
to de-prescribe)

Reeve, To,
Hendrix,
Shakib,
Roberts,
weise/2013

Identification of
potential
barriers and
facilitators
leading to a
patient decision
to agree to deprescribe
Systematic
review

N= 21

More facilitating factors than
barriers
Content analysis with coding

Variability in completeness of
reporting

Data extracted via two reviewers
through standardized data
extraction

Utilization of quantitative and
qualitative studies

Method included principles of
systematic review of quantitative
and qualitative research

Uncertainty of true
inappropriateness of a medication
in question for de-prescription.

Categories determined at time of
review
Data was extracted and
categorized then divided into
themes and subthemes

Studies included all age groups,
the variation between adolescence
and elderly must be considered.
Themes were found to be similar.

Quality assessment based on the
COREQ criteria
Themes identified:

Only able to use published data,
which equates to an inability to
support the idea that the only
factors relevant to prescribing are
the factors discussed in this
article

C
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1) Viewpoint regarding
“appropriateness” of deprescription
2) Availability of a process for
de-prescribing
3) Influences
4) Fright or dislike
Most common was
“appropriateness of deprescribing- 18 studies found it
to be a facilitator, 15 found it to
be a barrier
20 studies on single medication
class or therapeutic group, a
single study on any chronic med
De-prescribing should be patient
centered
Patients need to be educated on
why the medication is
inappropriate (i.e., side effects
can occur at any time)

Studies focused only on
commonly utilized medications
Quality assessment was not
formal. Results were poor as most
studies had mixed methodology
Potential for personal and
publication bias as this is these
are qualitative studies
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Table 1
Abbreviations.
Randomized Control Trial (RCT)
Consolidated Criteria for Reporting Qualitative Research (COREQ)
Potentially inappropriate medications (PIMs)
Grades of Recommendation Assessment, Development and Evaluation (GRADE)
Optimizing Prescribing for Older People in Primary Care, a cluster-randomized controlled trial (OPTI-SCRIPT study)

